| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer | Chief Scientific Officer
1 company
Lyssikatos Joseph P is a Chief Scientific Officer at Enliven Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 17 sells.
Estimated insider holdings value: $33.4M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 29, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sell | 12,000 | $22.49 | $269,841.39 | -0.6% | +14.4% | -8.8% | |
| Jul 31, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sell | 3,099 | $27.56 | $85,399.45 | -0.3% | +8.1% | -28.7% | |
| Jul 29, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sell | 12,000 | $26.70 | $320,377.80 | -0.5% | +7.9% | -24.4% | |
| Jul 1, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sell | 12,000 | $22.89 | $274,736.40 | -1.1% | +12.5% | -13.4% | |
| May 29, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 12,000 | $21.73 | $260,800.14 | -85.0% | +5.8% | -16.8% | |
| Apr 29, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 12,000 | $17.92 | $214,987.75 | -92.2% | +49.3% | +4.8% | |
| Apr 11, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 30,000 | $25.04 | $751,332.00 | -100% | -3.2% | -30.7% | |
| Apr 1, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 12,000 | $18.60 | $223,145.71 | -55.3% | +20.1% | -0.1% | |
| Feb 29, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 12,000 | $16.42 | $197,006.30 | -86.9% | +33.6% | +30.4% | |
| Jan 29, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 12,000 | $15.85 | $190,256.40 | -100% | +7.5% | +27.1% |